Lone Star Takes $4.7B Bite Out of Lonza's Capsules Empire

Lone Star Funds, the Dallas-based private equity powerhouse managing over $90 billion in assets, has entered into a definitive agreement to acquire Lonza Group AG's Capsules & Health Ingredients (CHI) division for approximately $4.7 billion. The transaction, announced March 6, 2025, represents one of the largest pharmaceutical services acquisitions of the year and marks a significant strategic realignment for the Swiss life sciences giant.

The deal will carve out Lonza's entire capsules manufacturing and health ingredients operation, creating a standalone entity focused exclusively on the rapidly growing nutraceuticals and dietary supplement sectors. With 11 manufacturing facilities across three continents and approximately 3,200 employees, the division generated $1.3 billion in revenue during Lonza's most recent fiscal year, representing roughly 18% of the parent company's total sales.

For Lonza, the divestiture allows the company to sharpen its focus on its core biologics manufacturing business, where margins have historically been higher and growth prospects more robust. The Swiss firm has increasingly positioned itself as a contract development and manufacturing organization (CDMO) for complex biopharmaceuticals, particularly monoclonal antibodies and cell and gene therapies. The CHI division, while profitable, represented a lower-margin business segment that Lonza management deemed non-core to its long-term strategic vision.

The acquisition is being executed by Lone Star Fund XII, the firm's latest flagship vehicle, which closed on $7.2 billion in commitments last year. The fund has been actively deploying capital across healthcare and industrial sectors, with particular emphasis on carve-outs from larger corporate parents—a strategy that aligns perfectly with the Lonza transaction structure.

The global pharmaceutical capsules market has experienced sustained growth, driven by consumer preference for capsule-based delivery formats over traditional tablets and the explosive expansion of the dietary supplement industry. Market research firm Grand View Research projects the global capsules market will reach $3.8 billion by 2030, growing at a compound annual rate of 8.2% from current levels.

Lonza's CHI division holds a commanding position in this market, particularly in vegetarian and specialty capsules, where it competes directly with ACG Capsules and Capsugel (now part of Lonza's portfolio following earlier acquisitions). The business manufactures both hard and soft gelatin capsules, as well as HPMC (hydroxypropyl methylcellulose) vegetarian capsules, which have gained significant market share as consumers increasingly seek plant-based alternatives.

Beyond capsules manufacturing, the division operates a substantial health ingredients business producing specialized nutritional compounds, including collagen peptides, microencapsulated nutrients, and bioactive ingredients used in functional foods and beverages. This vertical integration—from ingredient production through final capsule filling—provides significant competitive advantages in quality control, supply chain resilience, and margin capture.

Industry analysts suggest Lone Star sees substantial value creation opportunities through operational improvements and strategic bolt-on acquisitions. "The capsules and health ingredients sector remains highly fragmented outside the top three players," noted Jonathan Meyer, managing director at Raymond James Healthcare Investment Banking. "A well-capitalized private equity owner could pursue an aggressive buy-and-build strategy to consolidate regional players and expand into emerging markets."

The $4.7 billion enterprise value represents approximately 3.6x the division's trailing twelve-month revenue and roughly 12-13x estimated EBITDA, according to sources familiar with the transaction. While the revenue multiple appears modest for a healthcare asset, the EBITDA multiple reflects the capital-intensive nature of capsules manufacturing and the business's current margin profile, which insiders peg at approximately 28-30% EBITDA margin.

Lone Star is financing the acquisition through a combination of fund equity and debt facilities. Goldman Sachs and JPMorgan Chase are providing approximately $2.8 billion in senior secured financing, with the remainder coming from Fund XII's committed capital. The debt package includes a $1.9 billion term loan B and a $900 million senior secured note tranche, resulting in a leverage ratio of approximately 4.5x net debt to EBITDA at close.

This leverage profile sits comfortably within typical ranges for healthcare services buyouts, providing Lone Star with meaningful financial flexibility for both organic growth investments and strategic acquisitions. The firm has secured commitments for an additional $400 million revolving credit facility to support working capital needs and provide acquisition capacity.

The transaction includes customary representations, warranties, and indemnifications, along with a transition services agreement under which Lonza will provide certain corporate support functions—including IT infrastructure, procurement services, and regulatory affairs support—for an 18-month period following close. This structured separation approach reduces execution risk and ensures business continuity during the standalone entity's formative period.

The deal is subject to customary regulatory approvals, including clearance from antitrust authorities in the United States, European Union, and China. Given the fragmented nature of the capsules market and limited competitive overlap with Lone Star's existing portfolio companies, antitrust concerns appear minimal, and sources close to the transaction expect unconditional approval.

In a signal of continuity and confidence, Lone Star has secured commitments from the CHI division's entire senior leadership team to remain with the business post-acquisition. Division President Marc Funk, who has led the capsules business for seven years, will continue as CEO of the standalone entity. Funk's retention is viewed as critical given his deep relationships with major pharmaceutical and nutraceutical customers, including Pfizer, Bayer, and Nature's Bounty.

For Lonza, the divestiture represents the culmination of a multi-year strategic review aimed at concentrating resources on its highest-growth, highest-margin business segments. The company's Biologics division, which manufactures active pharmaceutical ingredients and drug products for biopharmaceutical customers, has consistently delivered EBITDA margins in the 32-35% range—400 to 700 basis points higher than the capsules business.

CEO Pierre-Alain Ruffieux has been explicit about Lonza's strategic priorities since taking the helm in 2023. "Our focus is squarely on becoming the world's premier biologics CDMO," Ruffieux stated in the company's Q4 2024 earnings call. "We will continue to evaluate our portfolio and make decisions that position us optimally in the markets where we can deliver the most value to customers and shareholders."

The CHI divestiture follows Lonza's 2023 sale of its specialty ingredients business to private equity firm Bain Capital for $1.1 billion, further demonstrating management's commitment to portfolio rationalization. Combined, these two transactions will have generated approximately $5.8 billion in proceeds, which Lonza has earmarked for capacity expansion in its core biologics manufacturing network and potential strategic acquisitions in cell and gene therapy technologies.

Lonza's biologics order book has grown substantially, fueled by the ongoing shift toward biologic therapies across oncology, immunology, and rare diseases. The company recently announced plans to invest $1.2 billion in expanding its Visp, Switzerland manufacturing complex and an additional $800 million in its Portsmouth, New Hampshire facility. These investments will add approximately 240,000 liters of biologics manufacturing capacity over the next three years.

Market reaction to the announced divestiture has been generally positive, with Lonza's shares trading up 4.2% in Zurich in the days following the announcement. Analysts view the transaction as value-accretive, particularly given Lonza's ability to redeploy proceeds into higher-return biologics infrastructure. The sale also addresses investor concerns about Lonza's relatively low operating margins compared to pure-play biologics CDMOs like Samsung Biologics and WuXi Biologics.

The transaction faces regulatory scrutiny across multiple jurisdictions, but antitrust experts anticipate a smooth approval process. The capsules manufacturing industry remains competitive with at least eight major global players and dozens of regional manufacturers, making it unlikely regulators will identify competitive concerns. Lone Star's existing healthcare portfolio includes several pharmaceutical services businesses but none with direct capsules manufacturing operations.

In the United States, the transaction will undergo Hart-Scott-Rodino (HSR) review by the Federal Trade Commission, which typically examines deals above the current $119.5 million threshold. European Commission approval will be required given Lonza's substantial European operations, while China's State Administration for Market Regulation (SAMR) will review the transaction given the CHI division's manufacturing presence in Guangzhou and its significant customer base among Chinese pharmaceutical companies.

The Lonza capsules acquisition represents Lone Star's fourth major healthcare platform investment since 2022, signaling the firm's conviction in defensive, cash-generative healthcare services businesses. The strategy appears to prioritize businesses with recurring revenue models, essential service characteristics, and opportunities for operational improvement and consolidation.

Previous healthcare investments include the 2022 acquisition of Covenant Physician Partners, a multi-specialty physician group, for $1.4 billion, and the 2023 purchase of LifeStance Health's institutional pharmacy division for $890 million. These transactions share common characteristics with the CHI deal: stable, recurring revenue from long-term customer relationships, significant barriers to entry, and fragmented competitive landscapes amenable to buy-and-build strategies.

John Grayken, Lone Star's founder and chairman, has historically favored investments in essential service businesses with predictable cash flows that can support meaningful leverage. The firm's investment approach typically involves acquiring quality assets at reasonable multiples, implementing operational improvements, and pursuing strategic bolt-on acquisitions to drive growth and multiple expansion.

Industry observers note that the capsules and health ingredients sector offers substantial consolidation opportunities. While the top three players—currently Lonza's CHI division, ACG Capsules, and the legacy Capsugel business—control approximately 60% of global market share, the remaining 40% is split among dozens of smaller regional manufacturers. A well-capitalized acquirer could pursue an aggressive roll-up strategy, particularly in high-growth markets like India, Southeast Asia, and Latin America.

Sources familiar with Lone Star's investment thesis suggest the firm has identified multiple value creation levers for the CHI business. Primary among these is margin expansion through operational excellence initiatives, including manufacturing footprint optimization, procurement efficiencies, and automation investments. The business currently operates 11 facilities across North America, Europe, and Asia, with significant variation in capacity utilization and cost structures across sites.

Lone Star's operational improvement playbook typically involves engaging specialized consulting firms and industry operators to conduct detailed diagnostic reviews and implement best practices. The firm has developed particular expertise in pharmaceutical and healthcare manufacturing operations through its ownership of contract manufacturing organization Patheon (later sold to Thermo Fisher Scientific for $7.2 billion in 2017), where it successfully implemented lean manufacturing principles and drove EBITDA margin expansion of 600 basis points over a four-year ownership period.

The transaction will materially reshape the competitive dynamics of the global capsules manufacturing industry. With the CHI division operating as an independent, well-capitalized entity under private equity ownership, competitors can expect more aggressive pricing, enhanced customer service investments, and potentially a wave of bolt-on acquisitions targeting regional players.

ACG Capsules, the India-based global leader in empty hard capsules, has already begun preparing for increased competitive intensity. The company announced in January 2025 a $200 million capacity expansion program across its facilities in India, Brazil, and Egypt. Similarly, China-based Suheung Capsule has accelerated its international expansion plans, establishing new sales offices in Europe and North America.

For pharmaceutical and nutraceutical companies—the end customers of capsules manufacturing services—the transaction may present both opportunities and challenges. On one hand, a well-capitalized, standalone CHI business may invest more aggressively in innovation, particularly in plant-based capsule technologies and specialized delivery systems like delayed-release and enteric-coated capsules.

On the other hand, some customers have expressed concerns about potential service disruption during the ownership transition and whether a private equity-backed entity will maintain Lonza's historical commitment to quality and regulatory compliance. These concerns are somewhat mitigated by management continuity and Lone Star's track record in healthcare services, but customer retention will be a critical focus during the transition period.

Despite the strategic logic and financial structuring of the transaction, several risk factors merit attention. Integration risk tops the list, particularly the challenge of separating complex IT systems, shared procurement contracts, and intertwined regulatory filings from Lonza's broader corporate infrastructure.

The 18-month transition services agreement provides a buffer, but history suggests that carve-out transactions frequently encounter unforeseen complications. Customer concentration represents another consideration, with the CHI division's top ten customers accounting for approximately 45% of revenue. Loss of even one major customer relationship during the ownership transition could materially impact financial performance and debt service capacity.

Regulatory compliance risk deserves particular emphasis in the highly regulated pharmaceutical manufacturing sector. The CHI division's facilities operate under FDA, EMA, and other global regulatory authorities' oversight, with regular inspections and stringent quality standards. Any significant audit findings or production quality issues could result in facility shutdowns, product recalls, or customer contract terminations.

Commodity price volatility in key raw materials—particularly gelatin, which is subject to agricultural commodity price swings—presents ongoing margin risk. While the business has historically maintained pass-through pricing mechanisms with most customers, there is typically a 60-90 day lag between raw material cost changes and price adjustments, creating periodic margin compression during periods of rapid input cost inflation.

The parties expect to achieve regulatory clearances and close the transaction in the fourth quarter of 2025, approximately eight to nine months from announcement. This timeline aligns with typical carve-out transaction timetables, which average 6-12 months from signing to close depending on regulatory complexity and business separation requirements.

Upon close, Lone Star will immediately establish the business as an independent legal entity with its own board of directors. The firm has already begun recruiting independent directors with pharmaceutical manufacturing and nutraceutical industry expertise. The initial board will likely comprise seven members: three Lone Star nominees (including a managing director who will serve as chairman), CEO Marc Funk, and three independent directors with relevant industry experience.

The post-acquisition integration roadmap focuses on three primary phases. Phase one, covering the first six months post-close, emphasizes business stabilization, customer retention, and employee communication. Phase two, spanning months 6-18, will focus on operational assessment, efficiency initiatives, and strategic planning. Phase three, beginning in year two, will pivot to growth acceleration, including potential bolt-on acquisitions and new product development.

Lone Star has engaged McKinsey & Company to support the operational diagnostic and improvement initiative, with particular focus on manufacturing footprint optimization and procurement transformation. The firm has also retained specialized pharmaceutical manufacturing consultants to evaluate automation opportunities across the facility network, with potential capital investments of $150-200 million over three years to drive efficiency gains and capacity expansion.

While Lone Star's investment horizon typically ranges from four to seven years, the firm's exit strategy for the CHI business will depend heavily on market conditions and value creation success. The most probable exit scenarios include a strategic sale to a larger pharmaceutical services company, a secondary buyout to another private equity firm, or potentially a public market offering if the business achieves sufficient scale and profitability.

Strategic acquirers could include other pharmaceutical CDMOs seeking to expand their service offerings, such as Catalent, Thermo Fisher Scientific, or emerging Asian pharmaceutical services giants. The business could also attract interest from consumer health and nutraceutical companies seeking vertical integration into capsule manufacturing.

If Lone Star successfully executes its operational improvement and buy-and-build strategy, the business could potentially command an EBITDA multiple of 14-16x at exit, compared to the approximately 12-13x entry multiple. Combined with EBITDA growth from organic expansion and bolt-on acquisitions, the firm's base case exit value likely targets $6.5-7.5 billion, representing a gross multiple of invested capital of approximately 2.3-2.6x over a five to six-year hold period.

This return profile would align with Lone Star's historical performance across its healthcare services investments and provide attractive returns to the firm's limited partners, which include major pension funds, sovereign wealth funds, and university endowments globally.